Published in final edited form as:

Tetrahedron Lett. 2015 June 3; 56(23): 3473–3476. doi:10.1016/j.tetlet.2015.01.016.

Synthesis of a polymerizable, bivalent glycan mimetic of the HIV envelope spike gp120

Eric T. Sletten, Riley L. Svec, and Hien M. Nguyen

Department of Chemistry, University of Iowa, Iowa City, IA 52242, USA

Abstract

A synthetic study on the creation of a bivalent, ROMP capable monomer has the ability to be polymerized into the corresponding neo-glycopolymer mimetic of the surface glycans on gp120 envelope spike of the HIV virus. In our approach, we have developed a new strategy for orthogonally attaching both the terminal Man α 1-2Man disaccharide unit of the D1 arm of Man9GlcNAc2 of HIV gp120 and the terminal Man α 1-2 unit of its D2 arm to a bivalent scaffold to produce the corresponding polymerizable monomer. The Man α 1-2 saccharide moieties were assembled using a nickel catalyst, Ni(4-F-PhCN)₄(OTf)₂, to activate trihaloacetimidate donors under mild and operationally simple procedure.

Keywords

HIV; Glycopolymer; Carbohydrate Synthesis; Nickel Catalyzed

Human immunodeficiency virus (HIV) has evolved into one of the most threatening global viruses since its first isolation in 1983. Despite extensive research efforts in more than two decades, the conception of a synthetic HIV vaccine capable of eliciting broadly-neutralizing antibodies, has thus far proven elusive.¹ A principal explanation for this phenomenon focuses on the heavily glycosylated viral envelope, comprised of oligosaccharide fragments, which may disguise the virion from immune responses if they are recognized as “self”,² the virus also utilizes its “glycan shield” to prevent protein-specific antibodies from binding to the inner protein core.³ The isolation of carbohydrate-specific broadly-neutralizing antibody 2G12, capable of binding to HIV gp120's surface oligosaccharides,^{4,5} suggests that the carbohydrate shield of HIV could be considered as a potential target for neutralization.⁶ This elucidation inspired the use of glycan antigens towards the development of potential vaccines. Along with the 2G12 antibody, several other carbohydrate-specific broadly-

© 2015 Published by Elsevier Ltd.

This manuscript version is made available under the CC BY-NC-ND 4.0 license.

hien-nguyen@uiowa.edu Phone: 319-384-1887 Fax: 319-335-1270.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data associated with this article can be found in the online version, at <http://>

neutralizing antibodies (bnAbs) have been characterized from HIV-infected individuals, including PG9, PG16, PGT121–123, PGT125–128, and PGT135.^{1,7} Extensive studies on the binding between HIV gp120 and these bnAbs have resolved crystal structures that commonly show strong binding affinities between these antibodies and a terminal Man α 1-2Man disaccharide motif on the D1 arm of the *N*-linked Man₉GlcNAc₂ unit (**1**, Figure 1) of gp120. The crystal structure of 2G12 in particular revealed that approximately 85% of the contact with gp120 was through this terminal disaccharide unit,^{6,8–9} and that its unusual Fab domain-swapped structure provided for additional multivalent binding sites.^{6,10} This discovery suggests that a majority of the binding event may be conserved upon utilization of only a fraction of the Man₉GlcNAc₂ epitope. Our objective is to develop a glycan mimetic of HIV gp120 that potentially binds to glycan-specific bnAbs; this synthetic mimetic could subsequently be investigated for use as a potential HIV vaccination strategy.

To date, a number of scaffolds have been utilized to mimic the multivalent glycan surface of HIV gp120 such as galactose moieties,¹¹ cyclic peptides,¹² cholic acid¹³, PNA,¹⁴ RNA,¹⁵ dendrimers,¹⁶ and Q β phage.¹⁷ Each of these recent strategies used either a significant portion of the Man₉GlcNAc₂ unit or Man₉GlcNAc₂ in its entirety as their potential antigen.¹⁸ Our strategy as illustrated in Figure 1, employs just two arms of the Man₉GlcNAc₂ glycan, D1 and D2, which constitute a large majority of the overall interaction between the 2G12 antibody and gp120. By assimilating the D1 Man α 1-2Man disaccharide and the mannose terminus of the D2 arm into one epitope, it is hypothesized that a considerable overall interaction may be conserved without the necessity of preparing larger fragments of Man₉GlcNAc₂ oligosaccharide. This strategy will be accomplished through the use of bivalent, ROMP-capable linker possessing orthogonal functionalities (Figure 1).¹⁹ With sequential positioning of each saccharide unit onto this linker through an amide bond formation and a “click” reaction²⁰ with an azide unit, respectively, two simplified fragments of the natural Man₉GlcNAc₂ glycan were bound to a single scaffold to afford the corresponding monomer **2** (Figure 1). The distance between the C1-anomeric carbons in the mannose units has been measured to be 11.5 Å.²¹ For comparison, the distance between the two saccharide moieties in monomer **2** (Figure 1) has been calculated using solid state 3D-modeling software to be ~13 Å, placing the glycans within a suitable proximity to each other to undergo “force affinity” to their respective receptors brought on by the flexible, bivalent tethered linker. Furthermore, we selected the norbornene-based linker because it has been reported that this scaffold increases the structural rigidity of the resultant neoglycopolymer.²² Importantly, this polymerizable linker is also endowed with a bicyclic strained ring system that can be then cleaved with Grubbs I/III catalysts via a ring-opening metathesis polymerization (ROMP)^{23–26} in order to polymerize the synthetic glycan mimetic of HIV gp120 and promote multivalent binding.

This letter details the synthesis of our target epitope by presenting a monomer **2** (Figure 1) containing a D-mannosyl monosaccharide unit and a Man α (1-2)Man disaccharide covalently bound to the polymerizable linker as proof of concept. In order to accomplish this, the traditional Lewis acid (TMSOTf) and the Ni(4-F-PhCN)₄(OTf)₂ catalyst recently developed in our lab²⁷ were compared in the trihaloacetimidate glycosylation reactions. Our results demonstrate the ability of Ni(4-F-PhCN)₄(OTf)₂ as an efficient catalyst for activating

an acetimidate donor under a mild and operationally simple procedure. The construction of target monomer **2** (Figure 1) required a preparation of the two glycan fragments, each bearing a functional group that could be sequentially coupled to the bivalent, polymerizable scaffold. In our design, *para*-methoxybenzyl (PMB) ether protecting groups were chosen for the substrate hydroxyl groups at C-3, -4, and -6 position because post-polymerization hydrogenation allows for their removal and a reduction of the residual alkenes of the polymer to be achieved simultaneously. An acetyl protecting group was chosen for the C-2 hydroxyl group, so that it could be selectively removed and subsequently serve as an acceptor for another coupling iteration to produce the corresponding disaccharide. This synthetic sequence maximized efficiency as the glycosyl donor was readily converted to the acceptor. Additionally, two different imidates were employed in this sequence to investigate an optimal donor species.

With this approach in mind, the first step of the synthesis was the establishment of monosaccharide **7**, a mimetic of the terminus of the D2 arm. Linker **5** (Table 1) presents a terminal azide,²⁸ which upon reduction to the corresponding amine may facilitate an amide coupling to the carboxylic acid of the bivalent scaffold **13** (Scheme 3). Accordingly, coupling of linker **5** with Schmidt's trichloroacetimidate^{29,30} donor **3** was mediated by 10 mol% TMSOTf (Table 1, entry 1), providing the desired glycoside product **6** in 70% yield. We next attempted to substitute TMSOTf for Ni(4-F-PhCN)₄(OTf)₂ (entry 2), previously described by the Nguyen group to be successful in the formation of 1,2-*cis*-2-aminoglycosides.²⁷ This nickel catalyst efficiently activated trichloroacetimidate donor **3** at 25 °C, providing **6** in a similar yield (70%, entry 2). In comparison, use of TMSOTf to mediate the coupling at 25°C (entry 3) only resulted in decomposition of carbohydrate coupling partners. This result suggests that Ni(4-F-PhCN)₄(OTf)₂ is a much milder activating reagent than air- and moisture-sensitive TMSOTf in the promotion of the glycosylation at a more green and economical temperature. The nickel catalyst is also effective at facilitating the glycosylation of **5** with *N*-phenyl trifluoroacetimidate **4** (entry 5), although the reaction took longer to reach completion. Subsequent removal of the C2-acetyl group with K₂CO₃ produced acceptor **7** in 90% yield, prepared for another coupling iteration with donors **3** and **4** to generate disaccharide.

The advantage of the Ni(4-F-PhCN)₄(OTf)₂ catalyst over the conventional Lewis acid (e.g. TMSOTf) for imidate glycosylation was further demonstrated in the preparation of Manα-(1-2)Man disaccharide **8** (Table 2). The TMSOTf-mediated glycosylation of acceptor **7** with trichloroacetimidate donor **3** resulted in only a 17% yield of desired disaccharide **8** (entry 1); many different side products were observed including the formation of an orthoester, the [1,3]-rearrangement of trichloroacetimidate **3** to the trichloroacetamide, as well as a partial removal of the acid-labile PMB groups due to the acidic nature of TMSOTf. On the other hand, use of 10 mol% Ni(4-F-PhCN)₄(OTf)₂ catalyst (entry 3) improved the yield of the product **8** (17% → 30%), but undesired [1,3]-rearrangement trichloroacetamide was still observed in the coupling event.³¹ In order to prevent the trichloroacetamide byproduct, donor **4**, *N*-phenyltrifluoroacetimidate,³² was employed (entries 4 and 5). When Ni(4-F-PhCN)₄(OTf)₂ was utilized and the coupling reaction was heated to 35°C, a significant improvement in formation of the desired disaccharide **8** (58%, entry 5) was observed.

Subsequent removal of the C2-acetyl group furnished the terminal Man α 1-2Man disaccharide **9** of the D1 arm of Man $_9$ GlcNAc $_2$ moiety, which could then be “clicked” to scaffold **13** (Scheme 3).^{19,33}

In addition to effectively activating the PMB-ether protected donors **3** and **4** (Tables 1 and 2), Ni(4-F-PhCN) $_4$ (OTf) $_2$ catalyst was also suitable for activating perbenzoylated trichloroacetimidate donor **10** to give disaccharide **12** (Scheme 2) in 83% yield. This result suggests that the nickel catalyst is more effective at activating electron-deficient imidate donor **10** than its electron-donating counterparts **3** and **4**.

Next, was the creation of the terminal monosaccharide **12** of the D2 arm unit (Scheme 2). This was achieved in a one-pot reaction by simultaneously subjecting **6** to a Staudinger reduction of the azide functionality to the corresponding amine,³⁴ and a hydrolysis of the C2-acetyl protecting group, providing a 90% yield of **12** (Scheme 2).

With both glycans in hand, each with their respective linker-conjugate functionality, they were sequentially coupled to the bivalent polymerizable backbone **13**³³ to complete our preliminary target epitope **2** (Scheme 3). We selected norbornene-based scaffold **13** because it has been used to generate bivalent-brush polymers for drug-delivery applications³² and to mimic the native-like, multivalent motif found on chondroitin sulfate proteoglycans.²² In our approach, the newly-formed terminal monosaccharide amine **12** was then coupled to the carboxylic acid on **13** under standard EDCI-mediated conditions, leading to the formation of **14** in 78% yield (Scheme 3). Next, a survey of Sharpless-Huisgen copper(I)-catalyzed cycloaddition conditions^{20,35} with the terminal D1 arm disaccharide **9** was carried out. After gauging the efficiency of reactions with a number of c(I) sources, additives, and solvents, it was determined that optimal treatment of triazole **14** with disaccharide **9** using CuI and DBU in DMF at 50 °C generated the corresponding monomer **2** possessing a polymerizable backbone in 50% yield (Scheme 3) as the final product. We have determined that varying the amount of Grubbs I or III catalysts (0.5 – 5.0 mol%) led to a series of neo-glycopolymers from the norbornene-based scaffold with controllable molecular weights (M_n) and narrow polydispersities (PDI).³⁶ We have also determined that lowering the catalyst concentration produced glycopolymers with long chain lengths.³⁶ Longer polymers with narrower polydispersities might be advantageous for biological activity.³⁷ The most suitable length with the strongest avidity would be determined in subsequent biological studies.³⁸ Recent results have also illustrated that some of the bnAbs such as PG9 and PG16 require part of peptide segment of the antigen to bind to.^{15,39,40} We envision that this peptide portion could be coupled to glycopolymers generated from monomer **2** (Scheme 3) by investigating end-functionalization of the polymers during the quenching stage of ROMP with an amine group, which will subsequently serve as an attachment point.²²

In summary, we have developed a new strategy for orthogonally attaching both the terminal Man α 1-2Man disaccharide unit of the D1 arm of Man $_9$ GlcNAc $_2$ and the terminal Man α 1-2 unit of its D2 arm to a bivalent scaffold to produce the corresponding polymerizable monomer **2**. The Man α 1-2 saccharide moieties were prepared in good yield via the Ni(4-F-PhCN) $_4$ (OTf) $_2$ -mediated trihaloacetimidate glycosylation reactions. The ring-opening metathesis polymerization (ROMP) of monomer **2** and subsequent binding studies of its

corresponding neo-glycopolymers with the 2G12 and several other bnAbs are under investigation and will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Mathew McConnell and Dr. Ravi Loka for helpful suggestions and for providing bivalent polymerizable starting materials. ETS would like to thank the Graduate College at Iowa for Summer Research Fellowship. RLS is grateful for ACS Division of the Organic Chemistry SURF Research Fellowship. This work was supported by NIH (R01 GM098285).

References

1. (a) Nabel GJ. *Nature*. 2001; 410:1002–1007. [PubMed: 11309631] (b) Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. *Nat Immunol*. 2004; 5:233–236. [PubMed: 14985706] (c) Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. *Curr Opin HIV AIDS*. 2010; 5:428–434. (d) Kwong PD, Mascola JR, Nabel GJ. *Cold Spring Harb Perspect Biol*. 2011; 3:a007278.
2. (a) Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. *Nature*. 1998; 393:705–711. [PubMed: 9641684] (b) Walker LM, Huber M, Doores KJ, et al. *Nature*. 2011; 477:466–470. [PubMed: 21849977]
3. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. *Cell Host Microbe*. 2012; 12:396–407. [PubMed: 23084910]
4. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF 3rd, Burton DR, Ho DD. *J Virol*. 1995; 69:6609–6617. [PubMed: 7474069]
5. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore J, Katinger H. *J Virol*. 1996; 70:1100–1108. [PubMed: 8551569]
6. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. *Science*. 2003; 300:2065–2071. [PubMed: 12829775]
7. (a) Walker LM, Burton DR. *Curr Opin Immunol*. 2010; 22:358–366. [PubMed: 20299194] (b) Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. *PLoS Pathog*. 2010; 6:e1001028. [PubMed: 20700449] (c) Lavine CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, Yang X. *J Virol*. 2012; 86:2153–2164. [PubMed: 22156525]
8. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. *J Virol*. 2002; 76:7293–7305. [PubMed: 12072528]
9. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. *J Virol*. 2002; 76:7306–7321. [PubMed: 12072529]
10. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA. *Proc Nat Acad Sci*. 2005; 102:13372–13377. [PubMed: 16174734]
11. Wang LX, Ni J, Singh S, Li H. *Chem Biol*. 2004; 11:127–134. [PubMed: 15113002]
12. (a) Krauss IJ, Joyce JG, Finnefrock AC, Song HC, Dudkin VY, Geng X, Warren JD, Chastain M, Shiver JW, Danishefsky SJ. *J Am Chem Soc*. 2007; 129:11042–11044. [PubMed: 17711286] (b) Joyce JG, Krauss IJ, Song HC, Opalka DW, Grimm KM, Nahas dD, Esser MT, Hrin R, Feng M, Dudkin VY, Chastain M, Shiver JW, Danishefsky SJ. *Proc Natl Acad Sci*. 2008; 105:15684–15689. [PubMed: 18838688]
13. Wang J, Li H, Zou G, Wang LX. *Org Biomol Chem*. 2007; 5:1529–1540. [PubMed: 17571181]
14. Horiya S, Bailey JK, Temme SJ, Guillen-Schlippe YV, Krauss IJ. *J Am Chem Soc*. 2014; 136:5407–5415. [PubMed: 24645849]

15. Temme JS, Drzyzga M, MacPherson IS, Krauss IJ. *Chem Eur J*. 2013; 19:17291–17295. [PubMed: 24227340]
16. Wang S, Liang P, Astronomo RD, Hsu T, Hsieh S, Burton D, Wong C. *Proc Natl Acad Sci*. 2008; 105:3690–3695. [PubMed: 18310320]
17. Astronomo RD, Kaltgrad E, Udit AK, Wang S-K, Doores KJ, Huang C-Y, Pantophlet R, Paulson JC, Wong C-H, Finn MG, Burton DR. *Chem Biol*. 2010; 17:357–370. [PubMed: 20416507]
18. For representative review articles, see: (a) McReynolds KD, Gervay-Hague J. *Chem Rev*. 2007; 107:1533–1552. [PubMed: 17439183] (b) Wang LX. *Curr Opin Chem Biol*. 2013; 17:997–1005. [PubMed: 24466581] (c) Horiya S, MacPherson IS, Krauss IJ. *Nat Chem Biol*. 2014; 10:990–999. [PubMed: 25393493]
19. Johnson JA, Lu YL, Burts AO, Xia Y, Durrell AC, Tirrell DA, Grubbs RH. *Macromolecules*. 2010; 43:10326–10335. [PubMed: 21532937]
20. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem Int Ed*. 2002; 41:2596–2599.
21. Gorska K, Huang K-T, Chaloin O, Winssinger N. *Angew Chem Int Ed*. 2009; 48:7695–7700.
22. Lee S-G, Brown JM, Rogers CJ, Matson JB, Krishnamurthy C, Rawat M, Hsieh-Wilson LC. *Chem Sci*. 2010; 1:322–325. [PubMed: 21274421]
23. Kolonko EM, Pontrello JK, Mangold SL, Kiessling LL. *J Am Chem Soc*. 2009; 131:7327–7333. [PubMed: 19469577]
24. Conrad RM, Grubbs RH. *Angew Chem, Int Ed*. 2009; 48:8328–8330.
25. Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, Agnew BJ, Hsieh-Wilson LC. *J Am Chem Soc*. 2008; 130:11576–11577. [PubMed: 18683930]
26. Rawat M, Gama CI, Matson JB, Hsieh-Wilson LC. *J Am Chem Soc*. 2008; 130:2959–2961. [PubMed: 18275195]
27. (a) Mensah EA, Nguyen HM. *J Am Chem Soc*. 2009; 131:8778–8780. [PubMed: 19496537] (b) Mensah EA, Yu F, Nguyen HM. *J Am Chem Soc*. 2010; 132:14288–14302. [PubMed: 20860359] (c) Yu F, Nguyen HM. *J Org Chem*. 2012; 77:7330–7343. [PubMed: 22838405] (d) McConnell MS, Yu F, Nguyen HM. *Chem Commun*. 2013; 49:4313–4315. (e) McConnell MS, Mensah EA, Nguyen HM. *Carbohydr Res*. 2013; 381:146–152. [PubMed: 24121123]
28. Chopko CM, Lowden EL, Engler AC, Griffith LG, Hammond PT. *ACS Macro Lett*. 2012; 1:727–731. [PubMed: 24883233]
29. Schmidt RR, Michel J. *Angew Chem, Int Ed*. 1980; 19:731–732.
30. Swarts BM, Guo Z. *J Am Chem Soc*. 2010; 132:6648–6650. [PubMed: 20423078]
31. (a) Park NH, Nguyen HM. *Org Lett*. 2009; 11:2433–2436. [PubMed: 19473048] (b) McKay MJ, Park NH, Nguyen HM. *Chem Eur J*. 2014; 20:8691–8701. [PubMed: 24905328]
32. Tanaka H, Iwata Y, Takahashi D, Adachi M, Takahashi T. *J Am Chem Soc*. 2005; 127:1630–1631. [PubMed: 15700984]
33. (a) McCluskey A, Keane MA, Mudjee L-M, Sim ATR, Sakoff J, Quinn RJ. *Eur J Med Chem*. 2000; 35:957–964. [PubMed: 11121622] (b) Rulisek L, Sebek P, Havlas Z, Hrabal R, Capek P, Svatos A. *J Org Chem*. 2005; 70:6295–6302. [PubMed: 16050690] (c) Kwart H, Burchuk I. *J Am Chem Soc*. 1952; 74:3094–3097.
34. Arungundram S, Al-Mafraji K, Asong J, Leach FE, Amster IJ, Venot A, Turnbull JE, Boons G-J. *J Am Chem Soc*. 2009; 131:17394–17405. [PubMed: 19904943]
35. Thirumurugan P, Matosiuk D, Jozwiak K. *Chem Rev*. 2013; 113:4905–4979. [PubMed: 23531040]
36. The scaffold **13** has been used in our group as a polymerizable linker for generating the corresponding bivalent glycopolymers to study their interactions with concanavalin A using isothermal titration calorimetry.
37. Rawat M, Gaman CI, Matson JB, Hsieh-Wilson LC. *J Am Chem Soc*. 2008; 130:2959–2961. [PubMed: 18275195]
38. Based on Wong's recent dendrimer approach, the strongest binding affinity would be with 25 copies of Man₉ glycan, see reference ¹⁶.
39. (a) Aussadat B, Vohra Y, Park PK, Fernández-Tejada A, Alam SM, Dennison SM, Jaeger FH, Anasti K, Stewart S, Blinn JH, Liao H-X, Sodroski JG, Haynes BF, Danishefsky SJ. *J Am Chem Soc*. 2013; 135:13113–13120. [PubMed: 23915436] (b) Amin MN, McLellan JS, Huang W,

- Orwenyo J, Burton DR, Koff WC, Kwong PD, Wang L-X. Nat Chem Bio. 2013; 9:521–526. [PubMed: 23831758] (c) Alam SM, Dennison SM, Aussedat B, Vohra Y, Park PK, Fernandez-Tejada A, Stewart S, Jaeger FH, Anasti K, Blinn JH, Kepler TB, Bonsignori M, Liao H-X, Sodroski JG, Danishefsky SJ, Haynes BF. Proc Natl Acad Sci. 2013; 110:18214–18219. [PubMed: 24145434]
40. (a) Bailey JJ, Bundle DR. Org Biomol Chem. 2014; 12:2193–2213. [PubMed: 24549150] (b) Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R, Mesa KA, Berman PW. J Biol Chem. 2014; 289:20526–20542. [PubMed: 24872420]

Figure 1.
Simplification of Mang₉GlcNAc₂ oligosaccharide to polymerizable, bivalent glycan monomer

Scheme 1.

Nickel-Catalyzed Coupling with Electron-Deficient Donor

Scheme 2.

One-pot hydrolysis of acetyl and reduction of azide

Scheme 3.

Completion of the bivalent, polymerizable glycan monomer

Table 1

Glycosylation of azide linker with trihaloacetimidates

Entry	Donor	Catalyst	Temp (°C)	Time (h)	Yield (%) ^a
1	3	TMSOTf	-40	1	71
2	3	Ni(4-F-PhCN) ₄ (OTf) ₂	25	2	70
3	3	TMSOTf	25	1	Decomposition
4	4	TMSOTf	-40	1	59
5	4	Ni(4-F-PhCN) ₄ (OTf) ₂	25	16	60

^a Isolated yield

Table 2

Formation of the Man α (1-2)Man Disaccharide

Entry	Donor	Catalyst	Temp (°C)	Time (h)	Yield (%) ^a
1	3	TMSOTf	-40	1	17
2	3	TMSOTf	25	1	Decomposition
3	3	Ni(4-F-PhCN) ₄ (OTf) ₂	25	4	30
4	4	Ni(4-F-PhCN) ₄ (OTf) ₂	25	16	39
5	4	Ni(4-F-PhCN) ₄ (OTf) ₂	35	16	58

^a Isolated yield